WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
WuXi AppTec reported a 28.8% YoY increase in total revenue to RMB 12.44 billion and a 71.7% YoY increase in adjusted non-IFRS net profit to RMB 4.60 billion for Q1 2026. The company's backlog for Continuing Operations reached RMB 59.77 billion as of March 31, 2026, up 23.6% YoY.
WuXi AppTec, a global pharmaceutical CRDMO, announced its Q1 2026 financial results. Total revenue reached RMB 12.44 billion, up 28.8% YoY, with revenue from Continuing Operations up 39.4% YoY. Adjusted non-IFRS net profit was RMB 4.60 billion, a 71.7% YoY increase. The company's backlog for Continuing Operations was RMB 59.77 billion as of March 31, 2026, a 23.6% YoY increase. WuXi Chemistry's revenue reached RMB 10.62 billion, up 43.7% YoY, driven by pipeline progression and new capacity ramp-up. The company reaffirms its full-year guidance with strong confidence.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.